Esophageal cancer is one of the deadliest cancers with 5-year relative survival of only 20%. Almost 75% of patients are diagnosed with esophageal cancer at an advanced stage, which involves regional spread to the lymph nodes or distant metastasis. As a result, many patients experience trouble swallowing (dysphagia) because their tumor blocks the esophagus, making it very difficult, if not impossible, to orally feed. Dysphagia is currently managed by mechanical dilation of the esophagus and placement of a stent or local ablation. These options often have both limited efficacy and/or significant safety limitations. Therefore, there is still a significant need for safe solutions that can effectively relieve tumor occlusion. Padeliporfin VTP therapy is currently being evaluated for this indication.